Synergistic effect of genistein and zinc on bone components in the femoral-metaphyseal tissues of female rats

Effects of zinc and aprotinin on the healing of ulnar diaphyseal fractures in rabbits

The effects of zinc and aprotinin on fracture healing in experimentally induced fractures were investigated by means of histometric analyses and alkaline phosphatase histochemistry. Healthy 54 adult New Zealand White female rabbits were separated into three groups as control, zinc, and aprotinin treatment. The control animals did not receive any medicament; zinc sulphate was given orally to the rabbits in the Zn group for 15 days. Aprotinin was postoperatively infiltrated into the fracture area at the 3rdand 24thh following operation. Immobilization of fracture ends of all groups was similar throughout the experiment. The zinc administered group displayed the highest alkaline phosphatase positive cell level through the experiment. By day 30 after the operation, fibrocartilage and osseous tissues reached the highest levels in the zinc treated group. Based on the observation of augmented osseous tissue formation and increased alkaline phosphatase positive osteoblastic cell activity in the callus, it was conluded that Zn sulphate is a potent stimulator of bone formation by increasing mineralization in the fractured bone segments.

Evaluation of the Relationship Between Height and Zinc, Copper, Iron, Calcium, and Magnesium Levels in Healthy Young Children in Beijing, China

We evaluated the relationship between child (aged 6-36 months) height and blood zinc, copper, iron, calcium, and magnesium concentrations. We selected 840 children following a physical examination. Weight and supine length or standing height were measured according to the World Health Organization guidelines. Polarographic analysis was used to measure zinc, copper, iron, magnesium, and calcium levels. Differences in heights between groups with low vs. high mineral concentrations, stratified by sex and age, were compared by analysis of variance. Relationships between these five elements and heights were tested by multiple regression analysis. Zinc levels in the shorter group (height for age (HAZ) ≤ -0.3) were 135.84 ± 39.76 and 134.83 ± 37.57 μmol/L in boys and girls, respectively. Zinc concentrations in the taller group (HAZ > -0.3) were 142.50 ± 35.85 and 140.52 ± 35.80 μmol/L in boys and girls, respectively. The difference between the two height groups in boys and girls was statistically significant. Compared with those (143.06 ± 33.76 μmol/L) in the taller group, zinc concentration (131.30 ± 40.75 μmol/L) in the shorter group was significantly lower (p = 0.04) at age 6-12 months. Height was positively correlated with zinc level in children aged 6-12 months (p < 0.05). Zinc levels were positively correlated with calcium, magnesium, and iron concentrations in children aged 6-36 months (p < 0.05). Our results indicated that zinc levels and height are correlated, and zinc levels were related to calcium, magnesium, copper, and iron concentrations. Therefore, to ensure healthy development in children, blood levels of these five elements should be balanced.

The effect of zinc and phytoestrogen supplementation on the changes in mineral content of the femur of rats with chemically induced mammary carcinogenesis

The aim of this study was to assess skeletal effects of zinc or zinc with phytoestrogen (resveratrol or genistein) supplementation in an animal model of rats with DMBA-induced mammary carcinogenesis. The changes in bone parameters such as the length and mass were examined, as well as the changes in concentrations of selected minerals: calcium, magnesium, zinc, iron and phosphorus. Moreover, the investigations focused on finding the differences between the levels of iron and zinc in other tissues: the liver, spleen and serum of the examined rats. Fifty-six female Sprague-Dawley rats, 40 days old, were divided into four groups, regardless of the diets: standard (77mg Zn kg/food), zinc (4.6mg/mL via gavage), zinc (4.6mg/mL) plus resveratrol (0.2mg/kgbw), and zinc (4.6mg/mL) plus genistein (0.2mg/kgbw) for a period from 40 days until 20 weeks of age. The study rats were also treated with 7,12-dimethyl-1,2-benz[a]anthracene (DMBA) to induce mammary carcinogenesis. The applied diet and the advanced mammary cancer did not affect macrometric parameters of the rats' bones, but they strongly affected their mineral content. It was found that mammary cancer, irrespectively of the applied diet, significantly modified the iron level in the femur, liver, spleen and serum of the examined rats. In addition, zinc supplementation significantly lowered the levels of calcium, magnesium and phosphorus in the femur of rats with mammary cancer as compared with respective levels in the control group. So, it was found that additional supplementation with zinc, which is generally considered to be an antioxidant, with the co-existing mammary carcinoma, increased the unfavorable changes as concerns the stability of bone tissue. The appropriate combination of zinc and phytoestrogens (resveratrol or genistein) could help prevent or slow bone loss associated with a range of skeletal disorders in breast cancer.

Role of trace elements (Zn, Sr, Fe) in bone development: energy dispersive X-ray fluorescence study of rat bone and tooth tissue

Osteoporosis is one of the most common debilitating disease around the world and it is more and more established among young people. There are well known recommendations for nutrition of newborns and children concerning adequate calcium and vitamin D intake in order to maintain proper bone density. Nevertheless, important role in structure and function of a healthy bone tissue is played by an integration between all constituents including elements other than Ca, like trace elements, which control vital processes in bone tissue. It is important from scientific point of view as well as prevention of bone diseases, to monitor the mineralization process considering changes of the concentration of minerals during first stage of bone formation. This work presents studies of trace element (zinc, strontium, and iron) concentration in bones and teeth of Wistar rats at the age of 7, 14, and 28 days. Energy dispersive X-ray fluorescence (EDXRF) was used to examine mandibles, skulls, femurs, tibiae, and incisors. The quantitative analysis was performed using fundamental parameters method (FP). Zn and Sr concentrations were highest for the youngest individuals and decreased with age of rats, while Fe content was stable in bone matrix for most studied bones. Our results reveal the necessity of monitoring concentration of not only major, but also minor elements, because the trace elements play special role in the first period of bone development.

Effects of different doses of ferutinin on bone formation/resorption in ovariectomized rats

This study analyzes the effects of different doses of ferutinin on bone loss caused by estrogen deficiency in ovariectomized rats, in comparison with estradiol benzoate. Thirty female Sprague-Dawley rats were ovariectomized and treated for 30 days from the day after ovariectomy. Static/dynamic histomorphometric analyses were performed on trabecular and cortical bone of lumbar vertebrae and femurs. Very low weight increments were recorded only in all F-OVX groups, with respect to the others. Although the great differences in weight, that could imply a decrease of bone mass in F-OVX groups compared to the control ovariectomized group (C-OVX), trabecular bone in lumbar vertebrae did not show significant differences, suggesting that ferutinin, opposing estrogen deficiency, inhibits bone resorption. Newly formed cortical bone was always low in all F-OVX groups and high in C-OVX, suggesting that it is mainly devoted in answering mechanical demands. In contrast, in distal femoral metaphyses, trabecular bone was reduced and the number of osteoclasts was increased in C-OVX with respect to all other groups, suggesting that it is mainly devoted in answering metabolic demands; moreover, ferutinin dose of 2 mg/kg seemed to be more effective than the lower doses used and estrogens, particularly in those skeletal regions with higher metabolic activity. Our results suggest that the role of ferutinin in preventing osteoporosis caused by estrogen deficiency is expressed in decreasing bone erosion; moreover, in all F-OVX groups bone turnover is very low and seems correlated to the trivial body weight increase, which, in turn, depends on ferutinin treatment.

Genistein aglycone effect on bone loss is not enhanced by supplemental calcium and vitamin D3: a dose ranging experimental study

Genistein aglycone (GEN) has a favorable effect on bone loss. We investigated the effects of GEN alone or in combination with supplemental calcium and vitamin D(3) in an animal model of bone loss to evaluate if there was additional benefit. Ovariectomized (OVX) and SHAM-OVX rats were used. OVX were divided into 12 groups and randomized to receive: GEN at 27, 54, 200, 500 or 1000 mg (human equivalent dose (HED)/day/ip injection alone or with calcium carbonate (Ca) (360 mg/kg/day/gavages) and vitamin D(3) (D(3)) (50 IU/kg/day/gavages) or Ca/D(3) without GEN or untreated for 6 weeks. SHAM-OVX were randomized into 7 groups and treated with: Ca and D(3) alone or in combination with GEN (same doses as OVX), or left untreated. Bone mineral density (BMD), bone-alkaline phosphatase (b-ALP), collagen C-telopeptides (CTX), osteoprotegerin (OPG) and soluble receptor activator of NFκB ligand (sRANKL) were assessed. Femurs were excised and tested for breaking strength and histology. Uterine weight was analyzed to assess GEN's estrogenic effects on the SHAM-OVX. The most effective dose of GEN, independent of Ca/D(3) supplementation, was 54 mg/day. Higher doses yielded no further improvement in bone biomarkers, histology or strength. Only 1000 mg/day HED of genistein produced statistically significant changes in uterine weight of the SHAM-OVX. This study suggests that 54 mg/day of GEN is the threshold dose for efficacy. In addition, supplemental calcium and vitamin D(3), beyond normal dietary intake do not enhance the effects of genistein on improving measures of bone loss. This observation has implications regarding the use of calcium and vitamin D(3) supplementation.

The effects of exercise and zinc deficiency on some elements in rats

The objective of the present study was to determine the effects of exercise and zinc deficiency on some elements in rats. Forty adult male Sprague-Dawley species male rats were allocated to four groups as follows: Group 1: control, Group 2: zinc-deficient, Group 3: exercise in which exercise group fed with a normal diet, Group 4: zinc-deficient exercise, exercise group fed by a zinc-deficient diet for 15 days. After the procedure ended, rats in groups 3 and 4 were exercised on the treadmill for 60 min at a speed of 6 m/min until the exhaustion. The rats were decapitated 48 h after exercise together with their controls, and blood samples were collected to determine copper (Cu), iron (Fe), magnesium (Mg), calcium (Ca), and phosphorus (P) levels. The highest Cu and Fe values in the serum were obtained in group 2 (p < 0.01). The levels of these elements in group 4 were lower than those in group 2 and higher than the levels in groups 1 and 3 (p < 0.01). Serum Mg levels did not differ significantly between groups. Group 4 had the lowest serum Ca and P levels (p < 0.01). These same parameters in Group 2 were higher than those in group 4 but significantly lower than those in groups 1 and 3 (p < 0.01). There was no significant difference between Ca and P levels of groups 1 and 3. The results of the study indicate that zinc deficiency adversely affects copper, iron, calcium, and phosphorus mechanisms and that these adverse effects much more marked after an effort exercise.

Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol

Background and purpose:

Genistein aglycone positively affects bone loss in postmenopausal women, but bone quality data are still lacking. To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in an animal model of established osteoporosis.

Experimental approach:

Six months after ovariectomy, 96 ovariectomized (OVX) rats were divided into 8 equal groups, randomized to treatments (genistein aglycone (1 and 10 mg kg⁻¹ s.c.); alendronate (0.003 and 0.03 mg kg⁻¹ s.c.); raloxifene hydrochloride (0.05 and 0.5 mg kg⁻¹ s.c.); 17-α-ethinyl oestradiol (0.003 and 0.03 mg kg⁻¹ s.c.)) for 12 weeks. Untreated OVX (n=12) and sham OVX (n=12) were used as controls. At the beginning and end of treatment, bone mineral density (BMD) and bone mineral content (BMC) were assessed. At the end of the experiment, calcium, phosphorus, bone-alkaline phosphatase (b-ALP), collagen C-telopeptide (CTX), osteoprotegerin (OPG) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) were assayed. Femurs were removed and tested for breaking strength and histology.

Key results:

Genistein (10 mg kg⁻¹) showed a greater increase in both BMD (P<0.0001 vs OVX) and BMC than all the other treatments. Moreover, genistein significantly increased breaking strength, bone quality, b-ALP (P<0.0001 vs OVX) and OPG, and reduced CTX and sRANKL compared with the other treatments at all dose levels.

Conclusions and implications:

The results strongly suggest that the genistein aglycone might be a new therapy for the management of postmenopausal osteoporosis in humans.

Genistein and zinc synergistically stimulate apoptotic cell death and suppress RANKL signaling-related gene expression in osteoclastic cells

The effects of the combination of genistein and zinc, which have an anabolic effect on bone metabolism, on osteoclastic cells in mouse marrow culture system in vitro was investigated. The macrophage colony-stimulating factor (M-CSF)-dependent bone marrow macrophages were cultured in the presence of M-CSF (10 ng/ml) and receptor activator of nuclear factor kappaB (NF-kB) ligand (RANKL; 50 ng/ml) for 4 days. The osteoclastic cells formed were further cultured in medium containing either vehicle, genistein, zinc sulfate (zinc), or genistein plus zinc with or without M-CSF (10 ng/ml) and RANKL (50 ng/ml) for 24 or 72 h. The number of osteoclastic cells was significantly decreased with culture of genistein (10(-6) M) plus zinc (10(-5) M) in presence or absence of M-CSF and RANKL for 24 or 72 h as compared with the value for genistein or zinc alone. Agarose gel electrophoresis showed the presence of low-molecular weight deoxyribonucleic acid (DNA) fragments of adherent cells cultured with genistein (10(-6) M) plus zinc (10(-5) M) for 24 or 72 h, indicating that the combination of two chemicals induces apoptotic cell death. Such an effect was not seen in the case of each chemical. Genistein plus zinc-induced decrease in osteoclastic cells were significantly inhibited in the presence of caspase-3 inhibitor (10(-8) or 10(-7) M). Culture with genistein (10(-6) M) plus zinc (10(-5) M) for 72 h caused a significant increase in caspase-3 mRNA expression in the presence or absence of M-CSF and RANKL as compared with the value for each chemical alone. Genistein plus zinc-induced increase in caspase-3 mRNA expression was completely inhibited in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB; 10(-6) M), an inhibitor of transcription activity. The mRNA expression of tartrate-resistant acid phosphatase (TRACP) or cathepsin K was significantly decreased with culture of genistein plus zinc in the presence of M-CSF and RANKL for 72 h as compared with genistein or zinc alone. Nuclear factor of activated T cells c1 (NFATc1) mRNA expression was significantly decreased with culture of genistein plus zinc in the presence of M-CSF and RANKL for 24 or 72 h as compared with each chemical alone, while NF-kB mRNA expression was significantly changed. This study demonstrates that the combination of genistein and zinc has potent stimulatory effects on apoptotic cell death and suppressive effects on osteoclastic cell function.

Zinc-containing phosphate-based glasses for tissue engineering

It has been shown that the addition of zinc to hydroxyapatite promotes osteoblast cell adhesion (Ishaug et al 1994 J. Biomed. Mater. Res. A 28 1445-53). Therefore, this study presents a series of phosphate-based glass compositions that contain varying amounts of zinc in order to promote osteoblast cell adhesion. The compositions investigated were P(50)Ca((40-x))Na(10) where x = 0, 1, 2, 3, 4 and 5 mol%. The dissolution rate and effect on pH of glass discs were investigated and ion release from the glass discs was examined in distilled water at 37 degrees C after 1, 2, 3, 4 and 7 days. The attachment of osteoblast-like cells (HOB) was observed by SEM on the glass discs. A linear decrease in the %mass of the glass discs was observed for all compositions for the duration of the study. The dissolution rates were similar for all the compositions. After 7 days, a mass loss of 3-6% was observed for all the compositions. The pH of distilled water decreased to a range of pH 4.5-5.5 from pH 7 after 1 day, and remained in this range for the duration of the study. The composition containing 0 mol% Zn reduced the pH to a lesser extent than the composition containing the highest amount of Zn. Furthermore, Zn(2+) ion release was observed from all the Zn-containing compositions. These glass compositions may therefore be suitable for tissue engineering applications.

Effects of phytoestrogenic isoflavones from red clover (Trifolium pratense L.) on experimental osteoporosis

The most common type of osteoporosis is bone loss associated with ovarian hormone deficiency at menopause. There is evidence that diets which contain high levels of phytoestrogenic isoflavones are associated with a low incidence of osteoporosis and menopausal symptoms. Plant extracts, which contain high levels of isoflavones, such as Red clover (Trifolium pratense L.), have been used to reduce menopausal symptoms. The objective of this study was to evaluate the preventive effects of Red clover total isoflavones on the progression of bone loss induced by estrogens deficiency (ovariectomy) in rats. Bilateral ovariectomy was performed on female Wistar rats. One week after the operation the rats were treated with an oral dose of 20 and 40 mg of total isoflavones daily for 14 weeks. The results from this study showed that the ovariectomy reduced bone mineral content, femoral weight, femoral density, mechanical strength of the tibia and increased the levels of bone specific alkaline phosphatase in the serum and the number of osteoclasts in the femur sections compared with sham operated controls. Treatment with isoflavones significantly increased bone mineral content, mechanical strength of the tibia, femoral weight, femoral density and prevented the rise of serum alkaline phosphatase levels. In addition, the treatment with isoflavones significantly reduced the number of osteoclasts compared with the ovariectomized control rats. These findings suggest that Red clover isoflavones are effective in reducing bone loss induced by ovariectomy, probably by reducing of the bone turnover via inhibition of bone resorption.

Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis

Aging induces a decrease in bone mass, and osteoporosis with its accompanying decrease in bone mass is widely recognized as a major public health problem. Bone loss with increasing age may be due to decreased bone formation and increased bone resorption. Pharmacologic and nutritional factors may prevent bone loss with aging, although chemical compounds in food and plants which act on bone metabolism are poorly understood. We have found that isoflavones (including genistein and daidzein), which are contained in soybeans, have a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption, thereby increasing bone mass. Menaquinone-7, an analogue of vitamin K(2) which is abundant in fermented soybeans, has been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption. Of various carotenoids, beta-cryptoxanthin, which is abundant in Satsuma mandarin (Citrus unchiu MARC), has a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption. The supplementation of these factors has a preventive effect on bone loss induced by ovariectomy in rats, which are an animal model of osteoporosis, and their intake has been shown to have a stimulatory effect on bone mass in humans. Factors with an anabolic effect on bone metabolism were found in extracts obtained from wasabi leafstalk (Wasabi japonica MATSUM), the marine alga Sargassum horneri, and bee pollen Cistus ladaniferus. Phytocomponent p-hydroxycinnamic acid was also found to have an anabolic effect on bone metabolism. Food chemical factors thus play a role in bone health and may be important in the prevention of bone loss with increasing age.

The effects of zinc deficiency and supplementation on lipid peroxidation in bone tissue of ovariectomized rats

This study aims at investigating how zinc deficiency and zinc application affect lipid peroxidation in bone tissue of ovariectomized rats. The study included 40 adult female rats of Sprague-Dawley species. Group 1 (n = 10): control group were fed with normal diet. Group 2 (n = 10): the group fed with normal diet after being ovariectomized. Group 3 (n = 10): the group fed with zinc-deficient diet for 6 weeks after ovariectomy. Group 4 (n = 10): the group which was given intraperitoneal zinc (3 mg/kg day zinc) in addition to normal diet for 6 weeks after ovariectomy. Malondialdehyde (MDA) and glutathione (GSH) levels were determined in erythrocyte, plasma and bone tissue. Group 3 had the highest plasma MDA levels compared to Groups 1, 2 and 4 (P < 0.05). These values were higher in Group 2 than in Groups 1 and 4 (P < 0.05). Bone and plasma MDA levels in Groups 1 and 4 were not different. Bone and erythrocyte GSH levels in Group 4 were higher than those in all other groups (P < 0.05). The lowest levels of bone and erythrocyte GSH levels were observed in Group 3 (P < 0.05). These values were higher in Group 2 when compared to those in Groups 1 and 3 (P < 0.05). This study demonstrate that zinc deficiency increased bone tissue damage in ovariectomized rats and that zinc supplementation prevented this damage.

Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study

The natural isoflavone phytoestrogen genistein has been shown to stimulate osteoblastic bone formation, inhibit osteoclastic bone resorption, and prevent bone loss in ovariectomized rats. However, no controlled clinical trial has been performed so far to evaluate the effects of the phytoestrogen on bone loss in postmenopausal women. We performed a randomized double-blind placebo-controlled study to evaluate and compare with hormone-replacement therapy (HRT) the effect of the phytoestrogen genistein on bone metabolism and bone mineral density (BMD) in postmenopausal women. Participants were 90 healthy ambulatory women who were 47-57 years of age, with a BMD at the femoral neck of <0.795 g/cm2. After a 4-week stabilization on a standard fat-reduced diet, participants of the study were randomly assigned to receive continuous HRT for 1 year (n = 30; 1 mg of 17beta-estradiol [E2] combined with 0.5 mg of norethisterone acetate), the phytoestrogen genistein (n = 30; 54 mg/day), or placebo (n = 30). Urinary excretion of pyridinoline (PYR) and deoxypyridinoline (DPYR) was not significantly modified by placebo administration either at 6 months or at 12 months. Genistein treatment significantly reduced the excretion of pyridinium cross-links at 6 months (PYR = -54 +/- 10%; DPYR = -55 +/- 13%; p < 0.001) and 12 months (PYR = -42 +/- 12%; DPYR = -44 +/- 16%; p < 0.001). A similar and not statistically different decrease in excretion of pyridinium cross-links was also observed in the postmenopausal women randomized to receive HRT. Placebo administration did not change the serum levels of the bone-specific ALP (B-ALP) and osteocalcin (bone Gla protein [BGP]). In contrast, administration of genistein markedly increased serum B-ALP and BGP either at 6 months (B-ALP = 23 +/- 4%; BGP = 29 +/- 11%; p < 0.005) or at 12 months (B-ALP = 25 +/- 7%; BGP = 37 +/- 16%; p < 0.05). Postmenopausal women treated with HRT had, in contrast, decreased serum B-ALP and BGP levels either at 6 months (B-ALP = -17 +/- 6%; BGP = -20 +/- 9%; p < 0.001) or 12 months (B-ALP = -20 +/- 5%; BGP = -22 +/- 10%; p < 0.001). Furthermore, at the end of the experimental period, genistein and HRT significantly increased BMD in the femur (femoral neck: genistein = 3.6 +/- 3%, HRT = 2.4 +/- 2%, placebo = -0.65 +/- 0.1%, and p < 0.001) and lumbar spine (genistein = 3 +/- 2%, HRT = 3.8 +/- 2.7%, placebo = -1.6 +/- 0.3%, and p < 0.001). This study confirms the genistein-positive effects on bone loss already observed in the experimental models of osteoporosis and indicates that the phytoestrogen reduces bone resorption and increases bone formation in postmenopausal women.

The positive effects of zinc on skeletal strength in growing rats

The aim of the present study was to assess the skeletal effects of alimentary zinc depletion and supplementation in an animal model of intact, growing rats. The study was planned as a dose-response study. Thirty-six male Wistar rats, 4 weeks old, were divided into three groups of 12 rats each. The rats had free access to a semisynthetic diet with different amounts of zinc added. Group 1 was given a zinc-free diet containing 2 mg zinc/kg, group 2 was given a normal-zinc diet containing 47 mg zinc/kg; and group 3 was given a zinc-supplemented diet containing 60 mg zinc/kg. All animals were killed 4 weeks after initiation of the experiment and the right femora were removed. The biomechanical effects were measured at the following skeletal sites: femoral diaphysis; femoral neck; and distal femoral metaphysis. In addition, static histomorphometry was performed at the middiaphyseal region. Biomechanical testing revealed a significant zinc-induced increase in bone strength at all sites investigated. It also showed that zinc influenced bone strength in a dose-dependent manner except at the distal metaphysis, where there was no significant difference between the group fed normal-zinc diet and the group fed a hyper-zinc diet. Zinc also improved the rates of growth in the rats. The body weights and length of femora increased dose-dependently. Static histomorphometry showed that zinc exerted its main effect on the periosteal envelope, thereby increasing bone area, tissue area, and axial moment of inertia. We conclude that alimentary zinc supplementation in growing rats induces an increase of bone strength in both the femoral neck and the femoral diaphysis. These results further support the view that zinc has a positive effect on bone metabolism which mimics that of growth hormone (GH) or insulin-like growth factor 1 (IGF-1).